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Abstract: We describe the validation of a serum-based test developed by Rules-Based Medicine which can be used to help confirm the 
diagnosis of schizophrenia. In preliminary studies using multiplex immunoassay profiling technology, we identified a disease signature 
comprised of 51 analytes which could distinguish schizophrenia (n = 250) from control (n = 230) subjects. In the next stage, these ana-
lytes were developed as a refined 51-plex immunoassay panel for validation using a large independent cohort of schizophrenia (n = 577) 
and control (n = 229) subjects. The resulting test yielded an overall sensitivity of 83% and specificity of 83% with a receiver operating 
characteristic area under the curve (ROC-AUC) of 89%. These 51 immunoassays and the associated decision rule delivered a sensitive 
and specific prediction for the presence of schizophrenia in patients compared to matched healthy controls.
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Introduction
Current diagnostic approaches for schizophrenia 
are based on patient interviews, which entail a sub-
jective assessment of clinical symptoms.1 There is 
increasing interest in the identification of molecular 
abnormalities that can be used to identify, stratify and 
monitor schizophrenia patients. Since longer periods 
of untreated psychosis are associated with poorer 
prognoses,2 an accurate test would enable early inter-
vention and improve patient outcomes, providing 
significant reductions of patient morbidity and health 
care costs. In addition, such a test would open up the 
possibility to stratify more accurately the disease and 
could represent a novel translational medicine tool, 
crucial for the discovery and development of more 
efficacious therapies.
One approach in development of a test for schizo-
phrenia is to find a biomarker signature that is capable 
of distinguishing schizophrenia patients from healthy 
controls. Many studies have identified molecules 
related to schizophrenia, but these are not likely to 
be useful as a disease test when used as single mark-
ers due to lack of specificity. Recent studies on other 
medical conditions using gene expression approaches 
have shown that multiplexed biomarkers can give 
reproducible results, which have proven useful in 
clinical applications.3
The recent development and application of multi-
plex immunoassay platforms allows the simultaneous 
measurement of many analytes from individual sam-
ples. The Rules-Based Medicine (Austin, TX, USA) 
DiscoveryMAPTM technology has already been applied 
successfully in numerous clinical studies  targeting dis-
eases such as epithelial ovarian cancer,4 scleroderma,5 
coronary artery disease,6 myocardial infarction,7 auto-
immune disorders8 and sickle cell anemia.9 This plat-
form is also suitable for the development of sensitive 
and specific tests for use in medical practice. With this 
in mind, we have used the DiscoveryMAP platform to 
profile serum samples from schizophrenia and control 
subjects.
The first objective of this multicenter study was 
to identify a set of analytes which were altered 
reproducibly in schizophrenia patients compared to 
matched healthy controls. The second objective was 
to use this analyte signature to construct a diagnostic 
decision rule, and then validate the signature for its 
utility as a laboratory developed test using another 
large cohort of schizophrenia patient and control 
samples. Both phases of this study were conducted 
in the Clinical Laboratory Improvement Amend-
ments (CLIA)-certified laboratory at Rules-Based 
Medicine.
Methods
The present study consisted of two phases (Fig. 1). 
The first phase was aimed at selection of accurate 
and reproducible schizophrenia biomarkers from 181 
assays comprising the Rules-Based Medicine Dis-
coveryMAP assay collection. Phase I resulted in the 
selection of 51 specific immunoassays to be used in 
assay validation. Phase II featured a refinement of 
the individual components of the multiplexed immu-
noassay, development of a decision rule for separat-
ing schizophrenia patients from normal controls, and 
validation of the decision rule using a cohort of 806 
clinical samples. For biological validation of the deci-
sion rule, 480 of these samples were only analyzed 
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validation
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during phase II of this study. The protocols for the 
study participants, clinical samples and test methods 
were carried out in compliance with the Standards 
for Reporting of Diagnostic Accuracy (STARD) 
initiative.10
study participants
Subjects were recruited from the Departments of 
Psychiatry at the Universities of Cologne (cohort 1), 
Muenster (cohort 2), Magdeburg (cohorts 3 and 4), 
 Rotterdam (cohort 5) and the US military (n = 110 
Bipolar Disorder patients and n = 110 controls). 
Cohorts used for the marker selection phase were 
comprised of 250 first- and recent-onset schizophre-
nia patients and 230 control subjects (Table 1A). 
 Schizophrenia patients of cohort 1 (n = 71), 2 (n = 46), 
4 (n = 47) and 5 (n = 40) were antipsychotic-naïve 
and 32 out of 46 subjects from cohort 3 had not been 
treated with antipsychotic medication for more than 6 
weeks prior to sample collection. Drug naïve patients 
are difficult to recruit since even large clinical facili-
ties can only expect to diagnose about 20–30 such 
patients each year. To facilitate the future develop-
ment of a test with differential diagnosis capability, 
we also carried out DiscoveryMAP analysis using 
samples from subjects within 30 days before their 
first contact with US military psychiatric services and 
who later received a confirmed diagnosis of bipolar 
disorder (BD) (n = 110, Table 1B). The cohort used 
to validate and implement the decision rule was com-
prised of samples from a mixture of first onset and 
chronic antipsychotic-treated schizophrenia patients 
along with healthy matched controls. The cohort orig-
inally consisted of a total of 838 subjects, 593 sub-
jects  diagnosed with schizophrenia and 245 matched 
healthy controls. During the laboratory testing of the 
Table 1A. Demographic details of subjects included in phase I (biomarker selection).
class cohort 1 2 3 4 5
control n 
M/F 
Age* 
BMI*
59 
31/28 
30 ± 8 
23 ± 4
46 
35/11 
27 ± 9 
na
45 
27/18 
34 ± 12 
24 ± 4
40 
33/07 
27 ± 4 
na
40 
26/14 
36 ± 11 
24 ± 3
schizophrenia 
first onset
n 
M/F 
Age* 
BMI*
71 
42/29 
31 ± 10 
24 ± 5
46 
35/11 
27 ± 9 
22 ± 2
46 
30/16 
35 ± 12 
26 ± 5
47 
36/11 
26 ± 8 
na
40 
27/13 
35 ± 10 
25 ± 5
*values are shown as mean ± sd.
samples, 32 samples were found to be of insufficient 
serum  quantity, leaving a final  validation population 
of 577 subjects diagnosed with schizophrenia and 229 
healthy, matched subjects recruited at the Universities 
of Cologne, Muenster and Magdeburg (Table 2).
Schizophrenia was diagnosed based on the Struc-
tured Clinical Interview for Diagnostic and Statisti-
cal Manual (DSM)-IV. Patients used for phase I of 
this study fulfilled the criteria of the paranoid subtype 
(DSM-IV 295.30). All diagnoses and clinical tests 
were performed by psychiatrists following Good Clin-
ical Practice guidelines. Patients whose clinical diag-
nosis required revision at a later stage were excluded 
from the study. Control subjects used in phase I of 
this study were matched to the schizophrenia patients 
for age, gender and social demographics and were 
recruited from the same economic and geographical 
area of the university districts. Controls with a fam-
ily history of mental disease or with other medical 
conditions such as type II diabetes, hypertension, car-
diovascular or autoimmune diseases were excluded 
from the study. Pre-symptomatic BD patients and 
respective controls (n = 110) were selected from a 
US military serum bank comprising approximately 
43 million sera, which facilitated matching for age, 
gender, ethnicity and lifestyle.
serum samples
The medical faculty ethical committees of the 
 respective research facilities approved the protocols 
of the study. Informed consent was given in writing 
by all participants recruited at universities and clini-
cal investigations were conducted according to the 
 principles expressed in the Declaration of  Helsinki. 
Blood samples were collected from all subjects 
between 8:00 and 12:00 hours into S-Monovette 
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7.5 mL serum tubes (Sarstedt; Numbrecht,  Germany). 
The samples were left at room temperature for 2 hours 
to allow for blood coagulation and then centrifuged at 
4000 × g for 5 minutes. The resulting supernatants 
were stored at -80 °C in Low Binding Eppendorf 
tubes (Hamburg, Germany).
DiscoveryMAP multiplex  
immunoassay profiling
Analytes were measured in 250 µL serum sam-
ples using the DiscoveryMAP multiplexed antigen 
 immunoassays in the CLIA-certified laboratory at 
Rules-Based Medicine. Assays were calibrated using 
duplicate 8-point standard curves and raw intensity 
measurements were converted to absolute protein con-
centrations using proprietary software. Machine per-
formance was verified using quality control samples 
at low, medium and high levels for each analyte. All 
standard and quality control samples were analyzed 
in a complex matrix to match the sample background. 
Serum samples were analyzed at optimized dilutions 
and analytes exceeding the highest concentrations 
on calibration curves were assigned the concentra-
tion of the highest standard, and those assayed below 
minimum concentrations were assigned the value 0.0. 
Assay reproducibility was assessed by reanalysis of 
the same samples approximately three months later 
by using Pearson’s correlation coefficients and moni-
toring the shift in average measurement levels.
Biomarker selection—phase I
The biomarker selection phase of the present study 
was aimed at identification of analytes that were 
altered reproducibly in schizophrenia compared to 
control subjects across independent cohorts (Fig. 1). 
Analytes were ranked based on the number of centers 
in which significant differences were observed using 
unpaired, two-tailed t-tests (P , 0.05). Analyte selec-
tion was guided by the following criteria: i) repro-
ducibility (including the same directional change) in 
three or more centers, ii) high correlation (.0.8) and 
low average measurement shifts (,40%) in repeat 
measurement (see above) and iii) mean experimen-
tal values distant from the least detectable dose (.20 
fold; LDD is defined as the average of the signal plus 
3 standard deviations of 20 blank samples analyzed at 
the same time).
51-plex development and clinical 
validation—phase II
Efficient analysis of the 51 analytes required con-
struction of new multiplexes. This procedure was 
guided by optimum dilution of serum and mixing 
of antibodies to give the most sensitive assays. The 
required dilutions of serum were 1:5, 1:50, 1:200, 
1:10,000, and 1:200,000. The 1:5 dilution group con-
sisted of 31 analytes which were divided into 4 mul-
tiplexes. For each higher dilution, only one multiplex 
was used, yielding a total of 8 new multiplexes for 
Table 2. Demographic details of 707 subjects used  during 
phase II (51-plex validation). 99 patient follow up  samples 
were available from cohort 2, yielding a total sample 
 number of 806.
class cohort 1 2 3
control n 
M/F 
Age* 
BMI*
72 
31/40* 
31 ± 9 
24 ± 3
84 
41/43 
37 ± 14 
na
73 
51/22 
34 ± 11 
25 ± 4
schizophrenia  
first onset 
 Drug naïve n 
M/F 
Age* 
BMI*
132 
78/54 
30 ± 9 
23 ± 4
18 
14/4 
28 ± 9 
22 ± 3
56 
36/20 
37 ± 11 
25 ± 5
 Treated n 
M/F 
Age* 
BMI*
130 
73/56* 
34 ± 12 
25 ± 5
71 
49/22 
26 ± 8 
24 ± 4
schizophrenia  
chronic
 Drug free n 
M/F 
Age* 
BMI*
11 
8/3 
32 ± 9 
26 ± 6
 Treated n 
M/F 
Age* 
BMI*
60 
32/28 
33 ± 9 
26 ± 5
*Demographic information for one patient not available.
Table 1B. Demographic details of pre-symptomatic bipo-
lar disorder and control subjects.
control n 
M/F 
Age*
110 
70/40 
21 ± 4
Pre-symptomatic Bipolar n 
M/F 
Age*
110 
70/40 
21 ± 4
*values are shown as mean ± sd.
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the 51 analytes. Once the multiplexes were created, 
large batches of reagents were manufactured to allow 
consistent testing of approximately 7000 samples. 
The reagents were validated using the following 
parameters: sensitivity, linearity, spike recovery, 
common serum matrix interferences, cross- reactivity, 
precision, correlation, freeze-thaw stability and short-
term room temperature antigen stability.
Classification decision rule—design 
and optimization
To discriminate schizophrenia patients from controls 
using the markers selected in phase I of this study, 
we implemented a linear support vector machine 
(SVM) algorithm. This method minimized errors by 
counting each misclassified observation with a pen-
alty parameter C. Specific penalty parameters were 
chosen for patients (CSZ) and controls (CNC), and the 
ratio F = CSZ /CNC was varied to modify the balance 
between sensitivity and specificity (visualised in a 
receiver operating characteristic (ROC) curve). Given 
a pair of parameters C and F, all elements of the data 
set were used to train the algorithm, and performance 
was measured using 10-fold cross validation (CV). 
The measured sensitivity and specificity calculated in 
each CV round were averaged and designated as the 
sensitivity and the specificity of the decision rule for 
the parameters C and F.
The optimization process was carried out using an in 
house developed code (Matlab 2009a). The search for 
optimal performance was performed among 3,100 pairs 
of parameters (C,F ) covering the following ranges: 
log2C = -10.0 to 0.0 with step 0.1 (100 values in total). 
log2F = -1.5 to +1.5 with step 0.1 (31 values in total).
We also computed the conditional probability C 
that a subject with a given score S is a schizophre-
nia patient. The computation of the conditional prob-
ability was based on the methodology developed by 
Vapnik.11 The conditional probabilities were used to 
augment the accuracy estimation of binary classifica-
tion decision rules with various levels of confidence.
Results and Discussion
schizophrenia biomarker  
selection—phase I
The first stage of the biomarker selection process 
resulted in the identification of 22 markers of the 
 DiscoveryMAP assay platform which were altered 
in the schizophrenia population in three or more of 
the clinical centers (Fig. 2A). Technical reproduc-
ibility was assessed by repeating the measurements 
(n = 63 subjects) approximately 3 months later. This 
showed an average correlation of 0.83, an average 
measurement shift of 29% and an average log dis-
tance to the LDD of 1.29. In contrast, analytes that 
were not selected featured an average correlation of 
0.65, measurement shift of 54% and log distance to 
the LDD of 0.70.
Nine additional biomarkers were incorporated 
into the 51-plex due to their known association with 
schizophrenia or due to the fact that we identified sig-
nificant changes in these analytes in studies of schizo-
phrenia patients using orthogonal platforms (Fig. 2B). 
In addition, we compared 110 pre-symptomatic bipo-
lar disorder patients with 110 matched controls and 
incorporated significant analytes (n = 20, parametric 
two-tailed t-test, P , 0.05) to facilitate the future 
development of a test with differential diagnosis 
capability (Fig. 2C).
Decision rule development 
and performance
New multiplexed immunoassays were developed 
which measured all 51 analytes. These were used 
to analyze a cohort of 806 subjects comprised of 
577 schizophrenia and 229 control subjects. For tech-
nical validation, these also contained 227 samples 
which had been used previously during the marker 
selection phase (phase I, Fig. 1) of the study. The aver-
age correlation for markers with high measurement 
quality (indicated by “+” in the correlation column of 
Fig. 2) between phase I and phase II using 84 controls 
out of the 227 samples was 0.86 (range: 0.71–0.99), 
indicating good reproducibility. Two classification 
decision rules were constructed using SVM. The first 
decision rule (SVM-A) was optimized to discriminate 
schizophrenia patients from controls in the combined 
dataset of 806 subjects. This yielded a cross-valida-
tion classification accuracy of 83% (sensitivity 83%, 
specificity 83%, ROC-AUC 89%). Since the cohort 
contained multiple samples from 99 antipsychotic-
treated patients, a second decision rule (SVM-B) was 
built using only the 707 unique samples. This decision 
rule also yielded a good separation between patients 
and controls with a cross-validation accuracy of 83% 
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(sensitivity 83%, specificity 82%, ROC-AUC 88%). 
Fig. 3A displays the classification accuracy and cor-
responding regions of conditional probabilities which 
are further detailed in Figure 3B. The conditional 
probability of correct classification of schizophrenia 
and control subjects increased with higher or lower 
scores relative to the decision boundary (Figure 3D 
lower panel).
To obtain an unbiased estimate of classifica-
tion performance and a biological validation of the 
schizophrenia analyte signature, we determined the 
performance of the decision rules in samples which 
had not been used for marker selection in phase I. 
Application of SVM-B (n = 480 subjects) yielded an 
overall  classification accuracy of 84% (conditional 
 probabilities are shown in Table 3). We also deter-
mined the classification accuracy of the SVM-B deci-
sion rule for four regions of conditional probabilities 
(Table 4). This resulted in an increase in accuracy of 
up to 96% for schizophrenia patients and up to 97% for 
controls in the highest probability regions (Table 4). 
When Region III was designated as indeterminate, 
17% of the total number of subjects were excluded 
(SVM-A, 20% for SVM-B).
Out of the 478 total schizophrenia patients included 
in phase II, 111 were suffering from a non-paranoid 
type of the disease (Table 5). SVM-A identified 95 
(86%) of these patients correctly suggesting that the 
biomarker signature was present regardless of the 
schizophrenia subtype.
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Figure 2. selection of analytes incorporated into the 51-plex. A) selection of 22 analytes was guided by (1) reproducible changes across independent 
cohorts of schizophrenia patients and controls (green plus; P , 0.05 in 3–5 cohorts), (2) consistent directional fold-change (green plus), (3) good cor-
relation (r . 0.8), (4) a low shift (,40%) between the first and second quality control measurements and (5) a high measurement to LDD ratio (.20:1) 
(X = lower, -- = not tested). B) 9 analytes were selected that are known to be involved in schizophrenia from the scientific literature or that we have identi-
fied as being differentially expressed using orthogonal platforms. c) 20 analytes were also selected which showed significant changes in bipolar disorder 
patients compared to controls.
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Table 3. Classification performance of SVM-B in phase II (51-plex development). Accuracy estimates are shown for the 
entire set of samples from unique patients as well as for the subset of 480 samples which were not used during phase I of 
the study. The conditional probability estimate is the median of all conditional probabilities in the respective group.
Group Subgroup sVM-B SVM-B (480 validation samples)
n Classification 
accuracy
conditional 
probability
n Classification 
accuracy
conditional 
probability
controls 229 83% 0.69 116 77% 0.61
schizophrenia Fe drug naive 189 77% 0.86 111 78% 0.85
Fe treated 201 85% 0.91 173 86% 0.91
chronic 71 96% 0.94 71 96% 0.94
Abbreviation: FE, first episode.
We also investigated 80 subjects (baseline Posi-
tive and Negative Syndrome Scale [PANSS] of 
66.0 ± 17.8) before and after 4–6 weeks of antip-
sychotic treatment which resulted in an overall 
reduction in symptoms of 13% (average reduction 
of 10.3 ± 17.3), as measured using the Positive and 
Negative Syndrome Scale (PANSS positive = 18% 
lower [average reduction of 3.7 ± 4.1], PANSS 
 negative = 8% lower [average reduction of 1.6 ± 4.9], 
PANSS general = 12% lower [average reduction of 
5.0 ± 8.5]).12 Interestingly, SVM-B was capable of 
identifying 85% of these patients at the first time-point 
and after the treatment period. There was an average 
correlation of 0.49 across all 51 analytes,  supporting 
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the stable identification capability of the decision 
rule. This suggested that schizophrenia patients in 
remission still feature schizophrenia-like serum pro-
files even after 4–6 weeks of treatment.
Conclusions
In this multicenter study, we discovered and validated 
a biomarker panel for schizophrenia based on bio-
logical and technical reproducibility of the molecular 
signature. All stages of the process, including con-
duction of the assays, analyte selection, biomarker 
panel refinement and development of the decision 
rule, were carried out in a CLIA-certified labora-
tory at Rules-Based Medicine. Biomarker selection 
was based on a large number of samples collected 
from antipsychotic naïve, acutely psychotic patients 
to facilitate relatively uniform conditions. Subjects 
were recruited from four independent clinical centers 
and samples were collected according to strict stan-
dard  operating  procedures to maximize  reliability and 
accuracy of the results. Biological variability arising 
from the collection in different geographical regions 
may contribute to the generality of the present find-
ings. Another factor which should be considered in 
this regard is that the samples were collected at the 
same centers for phases I and II of the study. How-
ever, as the data were generated from three inde-
pendent centers and from independent subjects, it is 
likely that the findings will be generalizable to other 
clinical centers. As the assay progresses from beta 
site testing to analysis in different subpopulations, 
the performance against present clinical classifica-
tion and observed prevalence and incidence must be 
monitored and differences will need examination.
The implementation of the 51 marker decision rule 
was based on a cohort comprised of both untreated 
and treated schizophrenia patients who were either 
 experiencing a first episode of illness or who were chron-
ically ill (54% of patients were on current  antipsychotic 
treatment). This collection is likely to represent more 
closely the patient population encountered in clinical 
practice. High classification performance demonstrated 
that the decision rule could identify schizophrenia 
patients with high accuracy irrespective of the disease 
duration or treatment state. Interestingly, the biomarker 
signal was still apparent in subjects even after 4–6 weeks 
of successful treatment with antipsychotic medication. 
This suggests that the 51-plex is robust for identification 
of subjects with schizophrenia at different stages of the 
schizophrenia disease process. Further work is required 
for the development of a biomarker panel aiding in the 
monitoring of patient responses to treatment.
In summary, the present findings demonstrate the 
applicability of a rapid and non-invasive test to  confirm 
the presence of schizophrenia. This first attempt to 
develop a molecular test with clinical utility for the 
Table 4. Classification performance of SVM-B in phase II (51-plex development). Accuracy estimates are shown for the 
entire set of samples from unique patients as well as for the subset of 480 samples which were not used during phase I of 
the study. Individual estimates are given for four regions of conditional probabilities.
probability 
region
conditional 
probability
sVM-B SVM-B (480 validation samples)
n patients 
(%)
n controls 
(%)
Classification 
accuracy#
n patients 
(%)
n controls 
(%)
Classification 
accuracy#
region I 1.00–0.91 234 (49%) 9 (4%) 96% 186 (51%) 0 (0%) 100%
region II 0.91–0.68 128 (27%) 17 (7%) 88% 119 (32%) 21 (18%) 85%
region IV* 0.60–0.83 31 (6%) 60 (26%) 73% 20 (5%) 39 (34%) 66%
region V* 0.83–0.84 2 (0.4%) 84 (37%) 97% 1 (0.2%) 21 (18%) 95%
*The conditional probabilities in regions marked with an asterisks reflect those determined for controls.
#Classification accuracies reflect the percentage of correct patient identifications in regions I and II and correct control identifications in regions IV and V.
Table 5. subtypes of the 478 schizophrenia patients 
 investigated in phase II of this study.
DSM-IV  
code
Subtype n
295.1 schizophrenia, disorganized type 18
295.2 schizophrenia, catatonic type 7
295.3 schizophrenia, paranoid type 367
295.4 schizophreniform disorder 26
295.6 schizophrenia, residual type 3
295.7 schizoaffective disorder 27
295.9 schizophrenia, undifferentiated type 15
297.1 Delusional disorder 1
Schizophrenia non specified 14
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diagnosis of schizophrenia was focused on the dis-
tinction of schizophrenia patients against healthy con-
trols. For this application, we have developed a refined 
51-plex assay panel and decision rule with a sensitivity 
and specificity of 83%. We anticipate that the 51-plex 
assay panel will result in the future development of a 
differential diagnostic test that can distinguish among 
various neuropsychiatric disorders such as schizophre-
nia, bipolar disorder and major depressive disorder. 
Therefore, the next stage towards clinical translation is 
to conduct a large scale clinical validation study using 
samples from diverse psychiatric patient populations 
and settings in a series of prospective studies with the 
Rules-Based Medicine assay platform.
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